# A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

> **NCT01472198** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 250 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Simtuzumab
- **DRUG:** Gemcitabine
- **DRUG:** Placebo to match simtuzumab

## Key facts

- **NCT ID:** NCT01472198
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-10
- **Final completion:** 2015-02
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2015-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472198, "A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01472198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*